CN102007132B - 结晶的(6r,7r)-7-{2-(5-氨基-[1,2,4]噻二唑-3-基)-2-[(z)三苯甲氧基亚氨基]-乙酰基氨基}-3-[(r)-1′-叔丁氧羰基-2-氧代-[1,3′]联吡咯烷-(3e)-亚基甲基]-8-氧代-5-硫杂-1-氮杂-二环并[4.2.0]辛-2-烯-2-甲酸二苯甲基酯、其制备及用途 - Google Patents
结晶的(6r,7r)-7-{2-(5-氨基-[1,2,4]噻二唑-3-基)-2-[(z)三苯甲氧基亚氨基]-乙酰基氨基}-3-[(r)-1′-叔丁氧羰基-2-氧代-[1,3′]联吡咯烷-(3e)-亚基甲基]-8-氧代-5-硫杂-1-氮杂-二环并[4.2.0]辛-2-烯-2-甲酸二苯甲基酯、其制备及用途 Download PDFInfo
- Publication number
- CN102007132B CN102007132B CN2009801134814A CN200980113481A CN102007132B CN 102007132 B CN102007132 B CN 102007132B CN 2009801134814 A CN2009801134814 A CN 2009801134814A CN 200980113481 A CN200980113481 A CN 200980113481A CN 102007132 B CN102007132 B CN 102007132B
- Authority
- CN
- China
- Prior art keywords
- compound
- dmso
- formula
- solvate
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 304
- 150000001875 compounds Chemical class 0.000 claims abstract description 152
- 239000012453 solvate Substances 0.000 claims abstract description 105
- 229960004241 ceftobiprole medocaril Drugs 0.000 claims abstract description 47
- ZVOFDXNPQLQATI-YAIQPWLKSA-N (6r,7r)-7-[[(2z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-3-[(e)-[1-[(3r)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]pyrrolidin-3-yl]-2-oxopyrrolidin-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic aci Chemical compound O1C(=O)OC(COC(=O)N2C[C@@H](CC2)N2C(C(=C/C=3CS[C@H]4N(C([C@H]4NC(=O)C(\N=O)=C\4N=C(N)SN/4)=O)C=3C(O)=O)/CC2)=O)=C1C ZVOFDXNPQLQATI-YAIQPWLKSA-N 0.000 claims abstract description 42
- 239000007787 solid Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 40
- 238000002425 crystallisation Methods 0.000 claims description 26
- 230000008025 crystallization Effects 0.000 claims description 25
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- -1 methoxyimino-acetylamino Chemical group 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 159000000000 sodium salts Chemical group 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 238000005893 bromination reaction Methods 0.000 claims description 2
- LKHYFCSSVZVVNF-UHFFFAOYSA-N ethyl hexanoate;sodium Chemical compound [Na].CCCCCC(=O)OCC LKHYFCSSVZVVNF-UHFFFAOYSA-N 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 239000012452 mother liquor Substances 0.000 claims description 2
- 238000005191 phase separation Methods 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- MFAWUGGPPMTWPU-INRVRKGJSA-M sodium (6R,7R)-7-[[(2E)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-3-[(E)-[1-[(3R)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]pyrrolidin-3-yl]-2-oxopyrrolidin-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].Cc1oc(=O)oc1COC(=O)N1CC[C@H](C1)N1CC\C(=C/C2=C(N3[C@H](SC2)[C@H](NC(=O)C(=N\O)\c2nsc(N)n2)C3=O)C([O-])=O)C1=O MFAWUGGPPMTWPU-INRVRKGJSA-M 0.000 claims 4
- 238000004821 distillation Methods 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- VOAZJEPQLGBXGO-SDAWRPRTSA-N ceftobiprole Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(\C=C/4C(N([C@H]5CNCC5)CC\4)=O)CS[C@@H]32)C(O)=O)=O)=N1 VOAZJEPQLGBXGO-SDAWRPRTSA-N 0.000 abstract 1
- 229950004259 ceftobiprole Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 150000001780 cephalosporins Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 229930186147 Cephalosporin Natural products 0.000 description 6
- 229940124587 cephalosporin Drugs 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NHNUFAASKXPOQA-UHFFFAOYSA-N (3-acetamido-2-hydroxyphenyl)arsonic acid Chemical compound C(C)(=O)NC=1C(=C(C=CC1)[As](O)(=O)O)O NHNUFAASKXPOQA-UHFFFAOYSA-N 0.000 description 1
- ZFHMQZAREIBMCO-BAFYGKSASA-N (6r)-4-chloro-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical compound C1=CC(Cl)S[C@@H]2CC(=O)N21 ZFHMQZAREIBMCO-BAFYGKSASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPBZMUTUWVOECC-UHFFFAOYSA-N C(OC=1OC(OC1C)=O)(OC)=O Chemical compound C(OC=1OC(OC1C)=O)(OC)=O CPBZMUTUWVOECC-UHFFFAOYSA-N 0.000 description 1
- VNCJDJVMMUNEGS-KBUSNVNASA-N CC(O1)=C(COC(N(CC2)CC2N(CC/C2=C\C(CS[C@@H]3[C@@H]4NC(/C(/c5n[s]c(N)n5)=N\O)=O)=C(C([NH+](C)[O-])=O)N3C4=O)C2=O)=O)OC1=O Chemical compound CC(O1)=C(COC(N(CC2)CC2N(CC/C2=C\C(CS[C@@H]3[C@@H]4NC(/C(/c5n[s]c(N)n5)=N\O)=O)=C(C([NH+](C)[O-])=O)N3C4=O)C2=O)=O)OC1=O VNCJDJVMMUNEGS-KBUSNVNASA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012492 regenerant Substances 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/48—Methylene radicals, substituted by hetero rings
- C07D501/54—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by an araliphatic carboxylic acid, which is substituted on the aliphatic radical by hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (28)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08154517 | 2008-04-15 | ||
EP08154517.0 | 2008-04-15 | ||
PCT/EP2009/054405 WO2009127623A1 (en) | 2008-04-15 | 2009-04-14 | Crystalline (6r,7r)-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(z)-trityloxyimino]-acetylamino}-3-[(r)-1'-tert-butoxycarbonyl-2-oxo-[1,3']bipyrrolidinyl-(3e)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102007132A CN102007132A (zh) | 2011-04-06 |
CN102007132B true CN102007132B (zh) | 2013-11-27 |
Family
ID=39708871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801134814A Active CN102007132B (zh) | 2008-04-15 | 2009-04-14 | 结晶的(6r,7r)-7-{2-(5-氨基-[1,2,4]噻二唑-3-基)-2-[(z)三苯甲氧基亚氨基]-乙酰基氨基}-3-[(r)-1′-叔丁氧羰基-2-氧代-[1,3′]联吡咯烷-(3e)-亚基甲基]-8-氧代-5-硫杂-1-氮杂-二环并[4.2.0]辛-2-烯-2-甲酸二苯甲基酯、其制备及用途 |
Country Status (22)
Country | Link |
---|---|
US (2) | US8865697B2 (zh) |
EP (1) | EP2268648B1 (zh) |
JP (1) | JP5451743B2 (zh) |
KR (1) | KR101493553B1 (zh) |
CN (1) | CN102007132B (zh) |
AR (1) | AR071318A1 (zh) |
AU (1) | AU2009237689B2 (zh) |
BR (1) | BRPI0911298A2 (zh) |
CA (1) | CA2721440C (zh) |
CY (1) | CY1112952T1 (zh) |
DK (1) | DK2268648T3 (zh) |
ES (1) | ES2387189T3 (zh) |
HK (1) | HK1154585A1 (zh) |
HR (1) | HRP20120467T1 (zh) |
MX (1) | MX2010011011A (zh) |
PL (1) | PL2268648T3 (zh) |
PT (1) | PT2268648E (zh) |
RS (1) | RS52350B (zh) |
SI (1) | SI2268648T1 (zh) |
TW (1) | TWI452048B (zh) |
WO (1) | WO2009127623A1 (zh) |
ZA (1) | ZA201007372B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012028678A2 (pt) * | 2010-05-10 | 2015-09-15 | Basilea Pharmaceutica Internat Ltd | processo de oxidação para preparar derivados de 3-formil-cefem |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237279A (en) * | 1979-07-27 | 1980-12-02 | Eli Lilly And Company | Crystalline 3-hydroxycephalosporin solvates |
US4734408A (en) * | 1986-12-17 | 1988-03-29 | Eli Lilly And Company | Crystalline cephalosporin antibiotic salts and solvates |
WO2001090111A1 (en) * | 2000-05-24 | 2001-11-29 | Basilea Pharmaceutica Ag | New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW415949B (en) | 1996-12-19 | 2000-12-21 | Hoffmann La Roche | Vinyl pyrrolidine cephalosporin derivatives with basic substituents |
GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
HUP0105426A3 (en) | 1998-06-15 | 2002-12-28 | Hoffmann La Roche | Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems and pharmaceutical compositions thereof |
US7141593B1 (en) * | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
JP2004530703A (ja) * | 2001-05-22 | 2004-10-07 | ファイザー・プロダクツ・インク | 結晶形アジスロマイシン |
US6821502B2 (en) * | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
US6903211B2 (en) * | 2002-10-30 | 2005-06-07 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of 3-propenyl cephalosporin DMF solvate |
AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
WO2007027525A1 (en) * | 2005-08-29 | 2007-03-08 | Sanofi-Aventis U.S. Llc | Novel crystalline form of a pyridazino [4 , 5-b] indole derivative |
WO2007073424A1 (en) * | 2005-09-13 | 2007-06-28 | Sicor, Inc. | Pure rocuronium bromide |
MX2009003405A (es) * | 2006-09-28 | 2009-04-09 | Merck & Co Inc | Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa. |
US7837978B2 (en) * | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
EP2160394A1 (en) * | 2007-05-22 | 2010-03-10 | Ultimorphix Technologies B.v. | Tenofovir disoproxil hemi-fumaric acid co-crystal |
TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
-
2009
- 2009-04-13 AR ARP090101291A patent/AR071318A1/es active IP Right Grant
- 2009-04-14 WO PCT/EP2009/054405 patent/WO2009127623A1/en active Application Filing
- 2009-04-14 JP JP2011504436A patent/JP5451743B2/ja active Active
- 2009-04-14 PL PL09731612T patent/PL2268648T3/pl unknown
- 2009-04-14 DK DK09731612.9T patent/DK2268648T3/da active
- 2009-04-14 PT PT09731612T patent/PT2268648E/pt unknown
- 2009-04-14 AU AU2009237689A patent/AU2009237689B2/en active Active
- 2009-04-14 TW TW098112362A patent/TWI452048B/zh active
- 2009-04-14 ES ES09731612T patent/ES2387189T3/es active Active
- 2009-04-14 SI SI200930290T patent/SI2268648T1/sl unknown
- 2009-04-14 BR BRPI0911298-7A patent/BRPI0911298A2/pt not_active Application Discontinuation
- 2009-04-14 EP EP09731612A patent/EP2268648B1/en active Active
- 2009-04-14 MX MX2010011011A patent/MX2010011011A/es active IP Right Grant
- 2009-04-14 CA CA2721440A patent/CA2721440C/en active Active
- 2009-04-14 CN CN2009801134814A patent/CN102007132B/zh active Active
- 2009-04-14 KR KR1020107025352A patent/KR101493553B1/ko active IP Right Grant
- 2009-04-14 US US12/937,607 patent/US8865697B2/en active Active
- 2009-04-14 RS RS20120287A patent/RS52350B/en unknown
-
2010
- 2010-10-14 ZA ZA2010/07372A patent/ZA201007372B/en unknown
-
2011
- 2011-08-23 HK HK11108903.6A patent/HK1154585A1/xx unknown
-
2012
- 2012-06-04 HR HRP20120467AT patent/HRP20120467T1/hr unknown
- 2012-08-07 CY CY20121100705T patent/CY1112952T1/el unknown
-
2014
- 2014-09-15 US US14/486,205 patent/US9163034B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237279A (en) * | 1979-07-27 | 1980-12-02 | Eli Lilly And Company | Crystalline 3-hydroxycephalosporin solvates |
US4734408A (en) * | 1986-12-17 | 1988-03-29 | Eli Lilly And Company | Crystalline cephalosporin antibiotic salts and solvates |
WO2001090111A1 (en) * | 2000-05-24 | 2001-11-29 | Basilea Pharmaceutica Ag | New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives |
Also Published As
Publication number | Publication date |
---|---|
KR101493553B1 (ko) | 2015-02-13 |
US20110137026A1 (en) | 2011-06-09 |
US8865697B2 (en) | 2014-10-21 |
JP2011516595A (ja) | 2011-05-26 |
AR071318A1 (es) | 2010-06-09 |
KR20110005714A (ko) | 2011-01-18 |
ES2387189T3 (es) | 2012-09-17 |
PT2268648E (pt) | 2012-07-24 |
BRPI0911298A2 (pt) | 2020-08-18 |
US9163034B2 (en) | 2015-10-20 |
TWI452048B (zh) | 2014-09-11 |
TW200946536A (en) | 2009-11-16 |
HK1154585A1 (en) | 2012-04-27 |
AU2009237689A1 (en) | 2009-10-22 |
MX2010011011A (es) | 2011-02-22 |
CA2721440A1 (en) | 2009-10-22 |
CN102007132A (zh) | 2011-04-06 |
WO2009127623A1 (en) | 2009-10-22 |
CY1112952T1 (el) | 2016-04-13 |
JP5451743B2 (ja) | 2014-03-26 |
PL2268648T3 (pl) | 2012-10-31 |
HRP20120467T1 (hr) | 2012-06-30 |
AU2009237689B2 (en) | 2014-01-16 |
US20150005491A1 (en) | 2015-01-01 |
EP2268648A1 (en) | 2011-01-05 |
EP2268648B1 (en) | 2012-05-16 |
CA2721440C (en) | 2012-12-11 |
SI2268648T1 (sl) | 2012-08-31 |
DK2268648T3 (da) | 2012-06-25 |
ZA201007372B (en) | 2011-06-29 |
RS52350B (en) | 2012-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2003136B1 (en) | Process for producing high-purity prasugrel hydrochloride | |
CN104619706B (zh) | 化学方法 | |
WO2016012470A1 (en) | New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid | |
US20090131665A1 (en) | Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI | |
JP2008543974A (ja) | ペメトレキセド二酸の結晶形およびその調製方法 | |
US9562050B2 (en) | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | |
US20090076272A1 (en) | Polymorphs of eszopiclone malate | |
CN102007132B (zh) | 结晶的(6r,7r)-7-{2-(5-氨基-[1,2,4]噻二唑-3-基)-2-[(z)三苯甲氧基亚氨基]-乙酰基氨基}-3-[(r)-1′-叔丁氧羰基-2-氧代-[1,3′]联吡咯烷-(3e)-亚基甲基]-8-氧代-5-硫杂-1-氮杂-二环并[4.2.0]辛-2-烯-2-甲酸二苯甲基酯、其制备及用途 | |
EP0637587A1 (en) | Bicyclic beta-lactam/paraben complexes | |
KR101408370B1 (ko) | 아리피프라졸-유기산 공결정을 함유하는 제제 및 이의 제조 방법 | |
JPH10511377A (ja) | セフォタキシムの製造 | |
JP4022070B2 (ja) | 新規チアゾール化合物およびその製造方法 | |
WO1998031683A1 (fr) | Nouveaux cristaux de z-valacyclovir | |
US20120220655A1 (en) | Crystalline forms of fesoterodine fumarate and fesoterodine base | |
CN106478666B (zh) | 7-氨基-3-甲氧甲基-3-头孢烯-4-羧酸的制备方法 | |
TWI551603B (zh) | 培美曲塞二酸之晶型及其製備方法 | |
US20220144768A1 (en) | Solid state forms of siponimod | |
US20220009929A1 (en) | Polymorphic forms of ibrutinib | |
JP3474635B2 (ja) | ロラカルベフ塩酸塩低級アルコール溶媒和物とその使用法 | |
JPWO2004085443A1 (ja) | 7−[2−(2−アミノチアゾール−4−イル)−2−ヒドロキシイミノアセトアミド−3−ビニル−3−セフェム−4−カルボン酸(シン異性体)の新規結晶およびその製造方法 | |
JP2618271B2 (ja) | モノp―ニトロベンジルマロネートマグネシウム塩の結晶変態及びその製法 | |
CN114685322B (zh) | 一种抗hiv类药物中间体晶体的生长方法和所得晶体及其应用 | |
CN107556328B (zh) | 制备头孢烯化合物的中间体及其晶体 | |
WO2006010978A1 (en) | Cefdinir polymorphic forms, and imidazole salt | |
CN114805220A (zh) | 一种喹唑啉酮类化合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1154585 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1154585 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20181012 Address after: Basel, Switzerland Patentee after: BASILEA PHARMACEUTICA INTERNATIONAL LTD. Address before: Basel, Switzerland Patentee before: BASILEA PHARMACEUTICA AG |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110406 Assignee: Shenzhen China Resources Gosun Pharmaceutical Co.,Ltd. Assignor: Basilea Pharmaceutica International Ltd. Contract record no.: 2019990000040 Denomination of invention: Fixed zymological method for production of prostaglandin E* Granted publication date: 20131127 License type: Exclusive License Record date: 20190201 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CP03 | Change of name, title or address |
Address after: Swiss Bonneville Patentee after: Basil Pharmaceuticals Allschwil International AG Address before: Basel, SUI Patentee before: BASILEA PHARMACEUTICA INTERNATIONAL LTD. |
|
CP03 | Change of name, title or address |